United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Currency in USD	2025
Operating Income	1.49 Billion
Income Before Tax	1.71 Billion
Income Tax Expense	379.20 Million
Net Income	1.33 Billion
Eps	30.13
Epsdiluted	27.86
Weighted Average Shs Out	44.30 Million
Weighted Average Shs Out Dil	47.90 Million
Research And Development Expenses	550.00 Million
Selling General And Administrative Expenses	755.80 Million
Depreciation And Amortization	85.60 Million
Interest Expense	19.50 Million
Interest Income	192.00 Million
Net Interest Income	172.50 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	2.80 Billion
Ebitda	1.58 Billion
Source	edgar
Ebit	1.73 Billion

United Therapeutics Corporation Annual Reports (10-K)